COHEN & STEERS INC (CNS) Fundamental Analysis & Valuation

NYSE:CNS • US19247A1007

Current stock price

60.83 USD
-1.11 (-1.79%)
At close:
60.83 USD
0 (0%)
After Hours:

This CNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. CNS Profitability Analysis

1.1 Basic Checks

  • In the past year CNS was profitable.
  • CNS had a negative operating cash flow in the past year.
  • In the past 5 years CNS has always been profitable.
  • Of the past 5 years CNS 4 years had a positive operating cash flow.
CNS Yearly Net Income VS EBIT VS OCF VS FCFCNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

1.2 Ratios

  • The Return On Assets of CNS (17.48%) is better than 96.23% of its industry peers.
  • Looking at the Return On Equity, with a value of 27.27%, CNS belongs to the top of the industry, outperforming 91.21% of the companies in the same industry.
  • CNS has a Return On Invested Capital of 20.96%. This is amongst the best in the industry. CNS outperforms 97.07% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CNS is significantly above the industry average of 7.28%.
Industry RankSector Rank
ROA 17.48%
ROE 27.27%
ROIC 20.96%
ROA(3y)17.87%
ROA(5y)24.39%
ROE(3y)30.23%
ROE(5y)44.84%
ROIC(3y)23.28%
ROIC(5y)32.89%
CNS Yearly ROA, ROE, ROICCNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • Looking at the Profit Margin, with a value of 27.66%, CNS is in the better half of the industry, outperforming 71.13% of the companies in the same industry.
  • In the last couple of years the Profit Margin of CNS has grown nicely.
  • With a decent Operating Margin value of 31.68%, CNS is doing good in the industry, outperforming 60.67% of the companies in the same industry.
  • In the last couple of years the Operating Margin of CNS has declined.
  • CNS has a Gross Margin of 86.84%. This is amongst the best in the industry. CNS outperforms 91.63% of its industry peers.
  • In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
Industry RankSector Rank
OM 31.68%
PM (TTM) 27.66%
GM 86.84%
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
CNS Yearly Profit, Operating, Gross MarginsCNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CNS Health Analysis

2.1 Basic Checks

  • CNS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CNS has been increased compared to 5 years ago.
  • There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CNS Yearly Shares OutstandingCNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CNS Yearly Total Debt VS Total AssetsCNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 7.19 indicates that CNS is not in any danger for bankruptcy at the moment.
  • CNS has a Altman-Z score of 7.19. This is amongst the best in the industry. CNS outperforms 91.21% of its industry peers.
  • CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.19
ROIC/WACCN/A
WACCN/A
CNS Yearly LT Debt VS Equity VS FCFCNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 0.98 indicates that CNS may have some problems paying its short term obligations.
  • CNS has a Current ratio (0.98) which is comparable to the rest of the industry.
  • A Quick Ratio of 0.98 indicates that CNS may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.98, CNS is in line with its industry, outperforming 43.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.98
CNS Yearly Current Assets VS Current LiabilitesCNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CNS Growth Analysis

3.1 Past

  • CNS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.80%.
  • CNS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.74% yearly.
  • CNS shows a small growth in Revenue. In the last year, the Revenue has grown by 7.04%.
  • Measured over the past years, CNS shows a small growth in Revenue. The Revenue has been growing by 5.73% on average per year.
EPS 1Y (TTM)5.8%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%3.85%
Revenue 1Y (TTM)7.04%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%17.21%

3.2 Future

  • CNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.66% yearly.
  • Based on estimates for the next years, CNS will show a small growth in Revenue. The Revenue will grow by 6.70% on average per year.
EPS Next Y8.82%
EPS Next 2Y10.9%
EPS Next 3Y8.22%
EPS Next 5Y8.66%
Revenue Next Year7.29%
Revenue Next 2Y9.14%
Revenue Next 3Y7.24%
Revenue Next 5Y6.7%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CNS Yearly Revenue VS EstimatesCNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
CNS Yearly EPS VS EstimatesCNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

2

4. CNS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 19.62, which indicates a rather expensive current valuation of CNS.
  • 65.27% of the companies in the same industry are cheaper than CNS, based on the Price/Earnings ratio.
  • CNS's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.88.
  • Based on the Price/Forward Earnings ratio of 18.03, the valuation of CNS can be described as rather expensive.
  • The rest of the industry has a similar Price/Forward Earnings ratio as CNS.
  • The average S&P500 Price/Forward Earnings ratio is at 22.19. CNS is around the same levels.
Industry RankSector Rank
PE 19.62
Fwd PE 18.03
CNS Price Earnings VS Forward Price EarningsCNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than 75.31% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.23
CNS Per share dataCNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • CNS has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.22
PEG (5Y)5.25
EPS Next 2Y10.9%
EPS Next 3Y8.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. CNS Dividend Analysis

5.1 Amount

  • CNS has a Yearly Dividend Yield of 4.25%, which is a nice return.
  • Compared to an average industry Dividend Yield of 6.73, CNS has a dividend in line with its industry peers.
  • CNS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.90.
Industry RankSector Rank
Dividend Yield 4.25%

5.2 History

  • The dividend of CNS decreases each year by -0.61%.
  • CNS has paid a dividend for at least 10 years, which is a reliable track record.
  • CNS has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-0.61%
Div Incr Years2
Div Non Decr Years2
CNS Yearly Dividends per shareCNS Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3

5.3 Sustainability

  • CNS pays out 82.84% of its income as dividend. This is not a sustainable payout ratio.
DP82.84%
EPS Next 2Y10.9%
EPS Next 3Y8.22%
CNS Yearly Income VS Free CF VS DividendCNS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M
CNS Dividend Payout.CNS Dividend Payout, showing the Payout Ratio.CNS Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

CNS Fundamentals: All Metrics, Ratios and Statistics

COHEN & STEERS INC

NYSE:CNS (3/27/2026, 7:00:00 PM)

After market: 60.83 0 (0%)

60.83

-1.11 (-1.79%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)01-22
Earnings (Next)04-14
Inst Owners56.27%
Inst Owner Change-2.29%
Ins Owners23%
Ins Owner Change5.46%
Market Cap3.13B
Revenue(TTM)553.87M
Net Income(TTM)153.22M
Analysts48
Price Target71.91 (18.21%)
Short Float %6.02%
Short Ratio4.83
Dividend
Industry RankSector Rank
Dividend Yield 4.25%
Yearly Dividend2.5
Dividend Growth(5Y)-0.61%
DP82.84%
Div Incr Years2
Div Non Decr Years2
Ex-Date03-09
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.25%
Min EPS beat(2)-0.99%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-1.02%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)2
Avg EPS beat(8)-1.07%
EPS beat(12)4
Avg EPS beat(12)0.08%
EPS beat(16)8
Avg EPS beat(16)0.68%
Revenue beat(2)1
Avg Revenue beat(2)0.17%
Min Revenue beat(2)-0.52%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.18%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.29%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.8%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.17%
Valuation
Industry RankSector Rank
PE 19.62
Fwd PE 18.03
P/S 5.64
P/FCF N/A
P/OCF N/A
P/B 5.56
P/tB 5.77
EV/EBITDA 16.23
EPS(TTM)3.1
EY5.1%
EPS(NY)3.37
Fwd EY5.55%
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.34
OCFYN/A
SpS10.78
BVpS10.94
TBVpS10.55
PEG (NY)2.22
PEG (5Y)5.25
Graham Number27.62
Profitability
Industry RankSector Rank
ROA 17.48%
ROE 27.27%
ROCE 27.12%
ROIC 20.96%
ROICexc 27.04%
ROICexgc 30.2%
OM 31.68%
PM (TTM) 27.66%
GM 86.84%
FCFM N/A
ROA(3y)17.87%
ROA(5y)24.39%
ROE(3y)30.23%
ROE(5y)44.84%
ROIC(3y)23.28%
ROIC(5y)32.89%
ROICexc(3y)33.62%
ROICexc(5y)61.08%
ROICexgc(3y)38.82%
ROICexgc(5y)75.29%
ROCE(3y)30.11%
ROCE(5y)42.55%
ROICexgc growth 3Y-33.24%
ROICexgc growth 5Y-15.16%
ROICexc growth 3Y-30.82%
ROICexc growth 5Y-13.86%
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
F-Score3
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 51.04%
Cap/Sales 1.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.98
Altman-Z 7.19
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)421.2%
Cap/Depr(5y)277.41%
Cap/Sales(3y)4.98%
Cap/Sales(5y)3.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.8%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%3.85%
EPS Next Y8.82%
EPS Next 2Y10.9%
EPS Next 3Y8.22%
EPS Next 5Y8.66%
Revenue 1Y (TTM)7.04%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%17.21%
Revenue Next Year7.29%
Revenue Next 2Y9.14%
Revenue Next 3Y7.24%
Revenue Next 5Y6.7%
EBIT growth 1Y1.51%
EBIT growth 3Y-4.78%
EBIT growth 5Y3.6%
EBIT Next Year-2.4%
EBIT Next 3Y14.61%
EBIT Next 5Y11.96%
FCF growth 1Y-248.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-224.57%
OCF growth 3YN/A
OCF growth 5YN/A

COHEN & STEERS INC / CNS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CNS.


What is the valuation status for CNS stock?

ChartMill assigns a valuation rating of 2 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.


Can you provide the profitability details for COHEN & STEERS INC?

COHEN & STEERS INC (CNS) has a profitability rating of 7 / 10.


Can you provide the financial health for CNS stock?

The financial health rating of COHEN & STEERS INC (CNS) is 6 / 10.


What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?

The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 8.82% in the next year.